Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease

Prostate Cancer (S Prasad, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Prostate Cancer


Purpose of Review

Androgen deprivation therapy (ADT) is a mainstay of treatment for advanced prostate cancer. Several studies have reported an association between ADT and an increase in cardiovascular events, especially in those receiving gonadotropin-releasing hormone (GnRH) agonists compared to GnRH antagonists. We review the body of literature reporting the association of ADT and cardiovascular morbidity, and discuss the proposed mechanism of cardiovascular disease due to ADT including metabolic changes that may promote atherosclerosis and local hormonal effects that may increase plaque rupture and thrombosis.

Recent Findings

GnRH agonists appear to increase the risk of cardiovascular morbidity by 20–25% in men on these agents compared those who do not receive ADT. GnRH antagonists may appear to have halve this risk while improving PSA progression-free survival.


GnRH antagonists may be superior to GnRH agonists for patients with significant cardiovascular disease, significant metastatic disease burden, or severe lower urinary tract symptoms.


Androgen deprivation Cardiovascular disease Gonadotropin-releasing hormone agonist Gonadotropin-releasing hormone antagonist Degarelix 


Compliance with Ethical Standards

Conflict of Interest

Alyssa K. Greiman declares no potential conflicts of interest. Thomas E. Keane reports consultancies for Ferring, Bayer, and Jannsen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
  2. 2.
    Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg. 1942;115(6):1192–200.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologyTM. Prostate cancer. National Comprehensive Cancer Network: Fort Washington, PA, Version 1. 2017. Available from: Accessed January 2017.
  5. 5.
    Mariani A, Glover M, Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol. 2001;165(1):104–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Drudge-Coates L. GnRH blockers: a changing paradigm in the management of prostate cancer. Int J Urol Nurs. 2009;3:85–92.CrossRefGoogle Scholar
  7. 7.
    Klotz L, Boccon–Gibod L, Shore N, Andreou C, Persson B, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Shore N. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013;5:11–24.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Keating N, O’Malley A, Smith M. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;23:4448–56.CrossRefGoogle Scholar
  10. 10.
    Tsai H, D’Amico A, Sadetsky N, Chen M, Carrol P. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Saigal C, Gore J, Krupski T, Hanley J, Schonlau M, Litwin M. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500.CrossRefPubMedGoogle Scholar
  12. 12.
    D’Amico A, Denham J, Crook J, Chen M, Goldhaber S, Lamb D, Joseph D, Tai K, Malone S, Ludgate C, Steigler A, Kantoff P. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.CrossRefPubMedGoogle Scholar
  13. 13.
    D’Amico A, Chen M, Renshaw A, Loffredo M, Kantoff P. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008;113:3290–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Levine G, D’Amico A, Berger P, Clark P, Eckel R, Keating N, Milani R, Sagalowsky A, Smith M, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. A science advisory from the American Heart Association, American Cancer Society, and American Urologic Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–40.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Studer U, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram S, Debois M, Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24:1868–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008;54:816–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Roach III M, Bae K, Speight J, Wolkov H, Rubin P, Lee R, Lawton C, Valicenti R, Grignon D, Pilepich M. Short-term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27:92–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bolla M, de Reijke T, Van Tienhoven G, Van den Bergh A, Oddens J, Poortmans P, Gez E, Kil P, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–27.CrossRefPubMedGoogle Scholar
  20. 20.
    • Klotz L, Miller K, Crawford D, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. Disease control outcomes from analysis of pooled individual patient data from five comparative randomized clinical trials of Degarelix versus lutenizing hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–8. Post hoc analysis of five prospective phase 3 or 3b randomized trials comparing the efficacy of GnRH agonists against an antagonist which showed improved overall survival and adverse events with degarelix CrossRefPubMedGoogle Scholar
  21. 21.
    •• Albertsen P, Klotz L, Bertrand T, Grady J, Olesen T, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–73. Post hoc analysis of six prospective randomized trials comparing the efficacy of GnRH agonists against an antagonist which found that GnRH antagonists halved the number of cardiac events experienced by men with pre-existing cardiovascular disease compared to GnRH agonists CrossRefPubMedGoogle Scholar
  22. 22.
    Huhtaniemi I, White R, McArdle C, Persson B. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009;20:43–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Varenhorst E, Wallentin L, Carlstrom K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol. 1982;16:31–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Millar R, Lu Z, Pawson A, Flanagan C, Morgan K, Maudsley S. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004 Apr;25(2):235–75.CrossRefPubMedGoogle Scholar
  25. 25.
    Harris W, Mostaghel E, Nelson P, Mongomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Calais da Silva F, Bono A, Whelan P, Brausi M, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269–77.CrossRefPubMedGoogle Scholar
  27. 27.
    Keating N, O’Malley A, Freeland S, Smith M. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration Web site. Accessed January 2017
  29. 29.
    Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28:3448–56.CrossRefPubMedGoogle Scholar
  30. 30.
    Martin-Merino E, Johansson S, Morris T, Garcia RL. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested-case-control study in UK primary care. Drug Saf. 2011;34(11):1061–77.CrossRefPubMedGoogle Scholar
  31. 31.
    Azoulay L, Yin H, Bernayoun S, Renoux C, Boivin J, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60(6):1244–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Hu J, Williams S, O’Malley A, Smith M, Nguyen P, Keating N. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61(6):1119–28.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Jespersen C, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704–9.CrossRefPubMedGoogle Scholar
  34. 34.
    • O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51. Multivariate analysis of a cohort of 41,362 men with prostate cancer on ADT compared to age-matched prostate cancer-free men which found a 21% increased risk of cardiovascular disease in men on GnRH agonists compared with the comparison cohort. This risk was highest in the first 6 months of therapy CrossRefPubMedGoogle Scholar
  35. 35.
    Alibhai S, Duong-Hua M, Sutradhar R, Fleshner N, Warde P, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, et al. The impact of the androgen deprivation therapy on the risk of coronary heart disease in patients with non-metastatic prostate cancer: a population-based study. BJU Int. 2014;114(6b):E82–9.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9(9):–e107516. Meta-analysis of six population-based observational studies comparing ADT versus control which found that GnRH therapy is associated with an increased risk of cardiovascular disease and cardiovascular mortality Google Scholar
  38. 38.
    •• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating N, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386–96. Meta-analysis of eight observational studies comparing ADT with control which found a relative risk of 1.38 for non-fatal cardiovascular disease in me non-GnRH agonist therapy compared to men not treated with ADT CrossRefPubMedGoogle Scholar
  39. 39.
    Punnen S, Cooperberg M, Sadetsky N, Carroll P. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011;29(26):3510–6.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wilcox C, Jautto A, Steigler A, Denham J. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology. 2012;82(1):56–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Nguyen P, Je Y, Schutz F, Hoffman K, Hu J, Parekh A, Beckman J, Choueiri T. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.CrossRefPubMedGoogle Scholar
  42. 42.
    Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–50.CrossRefPubMedGoogle Scholar
  43. 43.
    Jacobson J, Nisula B, Steinberg A. Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs. Endocrinology. 1994;134:2516–23.CrossRefPubMedGoogle Scholar
  44. 44.
    Chen H, Jueng E, Stephenson M, Leung P. Ribonucleic acids that are regulated by GnRH in vitro. Endocrinol Metab. 1999;84:743–50.Google Scholar
  45. 45.
    Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux P. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005;142:103–10.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Grasso G, Massai L, De Leo V, Muscettola M. The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro. Life Sci. 1998;62(22):2005–14.CrossRefPubMedGoogle Scholar
  47. 47.
    Andersson J, Libby P, Hansson G. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33–46.CrossRefPubMedGoogle Scholar
  48. 48.
    Dixit V, Yang H, Udhayakumar V, Sridaran R. Gonadotropin-releasing hormone alters the t helper cytokine balance in the pregnant rat. Biol Reprod. 2003;68:2215–21.CrossRefPubMedGoogle Scholar
  49. 49.
    Smith M, Klotz L, van der Meulen E, Colli E, Tanko L. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011;186:1935–842.Google Scholar
  50. 50.
    Tombal B, Miller K, Boccon-GIbod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57:836–42.CrossRefPubMedGoogle Scholar
  51. 51.
    Crawford E, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186:889–97.CrossRefPubMedGoogle Scholar
  52. 52.
    • Crawford E, Shore N, Moul J, Tombal B, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014;83(5):1122–8. The 5-year results from the cross-over trial of CS21 where patients receiving leuprolide were crossed over to degarelix after one year which showed a durable PSA progression-free survival benefit for degarelix over leuprolide at 5 years CrossRefPubMedGoogle Scholar
  53. 53.
    Hopmans S, Duivenvoorden W, Werstuck G, Klotz L, Pinthus J. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol. 2014;32(8):1126–34.CrossRefPubMedGoogle Scholar
  54. 54.
    Radu A, Pichon C, Camparo P, Antoine M, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–30.CrossRefPubMedGoogle Scholar
  55. 55.
    Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, Mommsen S, et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol. 2008;179:117–22.CrossRefPubMedGoogle Scholar
  56. 56.
    Schrӧder F, Tombal B, Miller K, Boccon-Gibod L, Shore N, Crawford E, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2009;106:182–7.CrossRefGoogle Scholar
  57. 57.
    Axcrona K, Aaltomaa S, Da Silva C, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110:1721–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Mason M, Maldonado P, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptoms relief and quality of life improvement in men with intermediate–to high-risk prostate cancer: a randomized non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol. 2013;25:190–6.CrossRefGoogle Scholar
  59. 59.
    Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT 00831233). Urol Int. 2013;90:321–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Bono A, Salvadore M, Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol. 2002;24:221–7.PubMedGoogle Scholar
  61. 61.
    Rick F, Schally A, Block N, et al. LHRH antagonist cetorelix reduces prostate size and gene expression of proinflammtory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2001;71:736–47.CrossRefGoogle Scholar
  62. 62.
    Giuliano F, Behr-Roussel D, Oger S, et al. Ozarelix, an LHRH antagonist, exerts a direct relaxing effect on human prostate in vitro. J Urol. 2009;181:693.CrossRefGoogle Scholar
  63. 63.
    Hatoum H, Crawford E, Nielsen S, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013;13:261–70.CrossRefPubMedGoogle Scholar
  64. 64.
    Lee D, Porter J, Gladwell D, Brereton N, Nielsen S. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. J Med Econ. 2014;17(4):233–47.CrossRefPubMedGoogle Scholar
  65. 65.
    Kelly D, Jones T. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217:24–45.Google Scholar
  66. 66.
    Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687–701.CrossRefPubMedGoogle Scholar
  67. 67.
    Zareba P, Duivenvoorden W, Leong D, Pinthus J. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8(2):118–29.CrossRefPubMedGoogle Scholar
  68. 68.
    Smith M. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008;9(3):197–202.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Smith M, Finkelstein J, McGovern F, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.CrossRefPubMedGoogle Scholar
  70. 70.
    Bourghardt J, Wilhelmson A, Alexandeson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151:5428–37.CrossRefPubMedGoogle Scholar
  71. 71.
    Falk E. Mophologic feature of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;3:114–20.CrossRefGoogle Scholar
  72. 72.
    Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009;50(suppl):S352–237.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Hansson G, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–12.CrossRefPubMedGoogle Scholar
  74. 74.
    Bhatia N, Santos M, Jones L, Beckman J, Penson D, Morgans A, Moslehi J. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537–41.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Jacobs E, Newton CC, Stevens V, Campbell P, Freedland S, Gapstur S. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol. 2014;32:3716–22.CrossRefPubMedGoogle Scholar
  76. 76.
    Conteduca V, Di Lorenzo G, Tartarone A, Aieta M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Ocol Hematol. 2013;8:2–51.Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of UrologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations